AstraZeneca (AZN) CEO Pascal Soriot said the company will maintain its 2025 sales guidance even if the U.S. levies tariffs on pharma products made in the European Union, provided the tariffs are in line with rates for other sectors, Reuters reports.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca reports Q1 core EPS $2.49, consensus $2.26
- AstraZeneca reports Q1 core EPS $2.49, consensus $1.12
- Puma Biotechnology announces data from neratinib trial at AACR meeting
- Sophia Genetics announces expanded collaboration with AstraZeneca
- Eli Lilly, Pfizer, Amgen – Trump’s 25% Pharma Tariffs Could Drain $51B Annually